堃博医疗-B（02216.HK）宣布，其产品Bronctru已成功获得中国国家药品监督管理局（NMPA）、美国食品药品监督管理局（FDA）以及欧盟医疗器械法规CE认证（mDR CE）的批准。同时，该产品亦在台湾、印度尼西亚、泰国和马来西亚等国家和地区获批上市，正式进入当地市场。
堃博医疗-B（02216.HK）宣布，其产品Bronctru已成功获得中国国家药品监督管理局（NMPA）、美国食品药品监督管理局（FDA）以及欧盟医疗器械法规CE认证（mDR CE）的批准。同时，该产品亦在台湾、印度尼西亚、泰国和马来西亚等国家和地区获批上市，正式进入当地市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.